Healthcare Blogs and Articles

Levetiracetam Reduces Amyloid-Β Production in the Brain

Researchers report that the FDA‑approved antiepileptic levetiracetam reduces amyloid‑β42 production in mouse models of Alzheimer’s disease. The drug redirects amyloid precursor protein processing toward the non‑amyloidogenic pathway by modifying synaptic vesicle cycling and increasing surface APP expression. Mass‑spectrometry and electrophysiology confirm lower Aβ42 levels, restored vesicle dynamics, and reduced synapse loss. These preclinical results suggest levetiracetam could be repurposed to test whether early reduction of amyloid pathology delays or prevents clinical Alzheimer’s onset.